GCK and Hypoglycemia: β-cell-targeted GCK transduction did not cause hypoglycemia, and intraperitoneal glucose tolerance test (IPGTT) conducted 2 weeks post vector administration showed no changes in glucose tolerance (Fig. 3C-E).